Peregrine Pharmaceuticals, Inc. (PPHM) F4Q10 (Qtr End 04/30/10) Earnings Call June 14, 2010 4:30 pm ET Executives Amy Figueroa – IR, BioCom Partners Steven King – President and CEO Rob Garnick – Head of Regulatory Affairs Joe Shan – VP, Clinical & Regulatory Affairs Chris Eso – VP, Business Operations Paul Lytle – CFO Analysts Joe Pantginis – Roth Capital Partners George Zavoico – MLV Roger Adams [ph] Ian Somaiya – Piper Jaffray PresentationOperator
Good day everyone, and welcome to the Peregrine Pharmaceuticals fourth quarter and fiscal year 2010 financial results conference call. (Operator instructions) I would now like to turn the conference over to Ms. Amy Figueroa. Please go ahead. Amy Figueroa Thanks, Paula. Good afternoon and thank you for joining us on today's call to discuss our financial results for the fourth quarter and fiscal year ended April 30, 2010 and review our clinical development program. Participating on today’s call are Steven King, President and Chief Executive Officer; Paul Lytle, Chief Financial Officer; Joe Shan, Vice President, Clinical and Regulatory Affairs; Rob Garnick, Head of Regulatory Affairs; and Chris Eso, Vice President of Business Operations. Before we begin, we would like to advise that this conference call includes forward-looking statements. These forward-looking statements reflect our current views about future events and financial performance that are identified by use of terms and phrases such as believes, expects, plans, anticipates, on target and similar expressions identifying forward-looking statements. These factors include but are not limited to, the risk factors detailed from time to time in our filings with the Securities and Exchange Commission, including but not limited to the Annual Report on Form 10-K for the year ended April 30, 2010 filed today.